The ocean is vast and unpredictable and supports a diverse array of life. CLINUVEL is navigating a turbulent ocean with a focused and committed team to diversify its activities to reach multiple patient groups and people with unmet and underserved needs.
During the financial year ending 30 June 2023 (FY2023), CLINUVEL continued to steer a defined course to maintain the commercial distribution of SCENESSE® (afamelanotide 16mg) to patients with erythropoietic protoporphyria (EPP). The Company’s melanocortin drug portfolio has expanded, to include PRÉNUMBRA® and NEURACTHEL®, to provide new treatment options for a range of indications. The expanded clinical program was advanced, specifically in DNA Repair, vitiligo, arterial ischaemic stroke and variegate porphyria.
CLINUVEL also commenced the translation of its technological know-how to the non-pharmaceutical sector. The first PhotoCosmetic product CYACÊLLE, was launched to targeted audiences in need of improved polychromatic protection from Ultraviolet (UV) and High Energy Visible (HEV) light. The planned PhotoCosmetic product range was outlined with emphasis on melanocortin based products to assist DNA repair and melanogenesis for risk-free tanning.
FY2023 marks the seventh consecutive year of positive revenues growth, net cash inflow and profitability, and the declaration of a sixth consecutive annual dividend. The balance sheet has been bolstered by the highest cash reserves ever achieved. Like the directional movement of a strong ocean current, this dynamic financial performance underpins CLINUVEL’s ability to advance its diversification initiatives. The Company’s expansion trajectory will continue into FY2024 and beyond to advance our objective to become an integrated, diversified and sustainable pharmaceutical group.